Search
Showing results for "aboriginal respiratory"
Research
Are you listening? The inaugural OMOZ Workshop - towards a better understanding of otitis mediaAre you listening? The inaugural OMOZ Workshop - towards a better understanding of otitis media
The Wesfarmers Centre is pleased to announce the successful applications for the 2016 Round 2 Wesfarmers Centre Seed Funding.
Research
Lung function trajectories throughout childhood in survivors of very preterm birth: a longitudinal cohort studyLung function trajectories are impaired in survivors of very preterm birth
Research
Hospitalisation for bronchiolitis in infants is more common after elective caesarean deliveryThe authors previously reported an increased risk of hospitalisation for acute lower respiratory infection up to age 2 years in children delivered by...
Research
PCV10 elicits Protein D IgG responses in Papua New Guinean children but has no impact on NTHi carriage in the first two years of lifeNasopharyngeal colonisation with nontypeable Haemophilus influenzae (NTHi) is associated with development of infections including pneumonia and otitis media. The 10-valent pneumococcal conjugate vaccine (PCV10) uses NTHi Protein D (PD) as a carrier. Papua New Guinean children have exceptionally early and dense NTHi carriage, and high rates of NTHi-associated disease.
Research
The Contribution of Geogenic Particulate Matter to Lung Disease in Indigenous ChildrenThe aim of this study was to assess the relationship between dust levels and health in Indigenous children in Western Australia
Research
Air trapping in early cystic fibrosis lung disease-Does CT tell the full story?Mosaic attenuation on expiratory chest computed tomography (CT) is common in early life cystic fibrosis (CF) and often referred to as "air trapping"
Research
The PneuCaPTIVE studyChristopher Deborah Blyth Lehmann MBBS (Hons) DCH FRACP FRCPA PhD AO, MBBS, MSc Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases;
Research
Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in AustraliaOur population-based cohort study demonstrates that >90% coverage in the first year of a universal 3 + 0 PCV program provided high population-level protection
Research
Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.Background: High incidence and serotype diversity of invasive pneumococcal disease (IPD) in Indigenous children in remote Australia led to rapid introduction of